Abstract
Osteopontin (OPN) is a matricellular protein that is produced by multiple tissues in our body and is most abundant in bone. It is also produced by cancer cells and plays a determinative role in the growth, progression and metastasis of cancer. Clinically, OPN has been reported to be upregulated in tumor cells per se; this is also reflected by increased levels of OPN in the circulation. Thus, increased OPN levels in the plasma are an effect of tumor growth and progression. Functionally, high OPN levels are determinative of higher incidence of bone metastases in mouse models and are clinically correlated with metastatic bone disease and bone resorption in advanced breast cancer patients. Several research efforts have been made to therapeutically target and inhibit the activities of OPN. In this article we have reviewed OPN in its role as an effector of critical steps in tumor progression and metastasis, with a particular emphasis on its role in facilitating bone metastasis of breast cancer. We have also addressed the role of the host-derived OPN in influencing the malignant behavior of the tumor cells.
Keywords: Osteopontin, cancer, bone, metastasis, secreted phosphoprotein 1
Current Molecular Medicine
Title: Osteopontin: An Effector and an Effect of Tumor Metastasis
Volume: 10 Issue: 1
Author(s): L. A. Shevde, S. Das, D. W. Clark and R. S. Samant
Affiliation:
Keywords: Osteopontin, cancer, bone, metastasis, secreted phosphoprotein 1
Abstract: Osteopontin (OPN) is a matricellular protein that is produced by multiple tissues in our body and is most abundant in bone. It is also produced by cancer cells and plays a determinative role in the growth, progression and metastasis of cancer. Clinically, OPN has been reported to be upregulated in tumor cells per se; this is also reflected by increased levels of OPN in the circulation. Thus, increased OPN levels in the plasma are an effect of tumor growth and progression. Functionally, high OPN levels are determinative of higher incidence of bone metastases in mouse models and are clinically correlated with metastatic bone disease and bone resorption in advanced breast cancer patients. Several research efforts have been made to therapeutically target and inhibit the activities of OPN. In this article we have reviewed OPN in its role as an effector of critical steps in tumor progression and metastasis, with a particular emphasis on its role in facilitating bone metastasis of breast cancer. We have also addressed the role of the host-derived OPN in influencing the malignant behavior of the tumor cells.
Export Options
About this article
Cite this article as:
Shevde A. L., Das S., Clark W. D. and Samant S. R., Osteopontin: An Effector and an Effect of Tumor Metastasis, Current Molecular Medicine 2010; 10 (1) . https://dx.doi.org/10.2174/156652410791065381
DOI https://dx.doi.org/10.2174/156652410791065381 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Adrenomedullin Function in Vascular Endothelial Cells: Insights from Genetic Mouse Models
Current Hypertension Reviews Lipid-Based Drug Delivery Systems for Cancer Treatment
Current Drug Targets Chitinases: Biomarkers for Human Diseases
Protein & Peptide Letters Membrane Localization of Estrogen Receptors
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Acute Hypersensitivity Reactions to Chemotherapy Agents: An Overview
Inflammation & Allergy - Drug Targets (Discontinued) Methylglyoxal and Advanced Glycation Endproducts: New Therapeutic Horizons?
Recent Patents on Cardiovascular Drug Discovery Cannabinoids and Cancer
Mini-Reviews in Medicinal Chemistry Estrogen Receptors as Targets for Drug Development for Breast Cancer, Osteoporosis and Cardiovascular Diseases
Current Cancer Drug Targets Xeno-Cannibalism as an Exacerbation of Self-Cannibalism: A Possible Fruitful Survival Strategy for Cancer Cells
Current Pharmaceutical Design Recent Development of Peptide Drugs and Advance on Theory and Methodology of Peptide Inhibitor Design
Medicinal Chemistry Triazole-linked Chalcone and Flavone Hybrid Compounds Based on AZT Exhibiting In Vitro Anti-Cancer Activity
Letters in Drug Design & Discovery Cushing's Syndrome and Steroid Dementia
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) lGnRH-III - a Promising Candidate for Anticancer Drug Development
Protein & Peptide Letters Overview of Base Excision Repair Biochemistry
Current Molecular Pharmacology A Tropical Lichen, Dirinaria consimilis Selectively Induces Apoptosis in MCF-7 Cells through the Regulation of p53 and Caspase-Cascade Pathway
Anti-Cancer Agents in Medicinal Chemistry The Influences of Aconitine, an Active/Toxic Alkaloid from Aconitum, on the Oral Pharmacokinetics of CYP3A Probe Drug Buspirone in Rats
Drug Metabolism Letters Paclitaxel Resistance: Molecular Mechanisms and Pharmacologic Manipulation
Current Cancer Drug Targets <i>In Vivo</i> Evaluation of Inorganic Nanoparticle Complexes against CCL<sub>4</sub> Induced Hepatotoxicity
Current Drug Delivery Novel Agents Targeting Bioactive Sphingolipids for the Treatment of Cancer
Current Medicinal Chemistry Human Cancer Cell Line Based Approach of 1,3,4-thiadiazole and its Fused Ring: A Comprehensive Review
Anti-Cancer Agents in Medicinal Chemistry